Results 211 to 220 of about 50,773 (265)

Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials. [PDF]

J Crohns Colitis
Vermeire S, Sands BE, Peyrin-Biroulet L, D'Haens GR, Panés J, Yarur AJ, Wolf DC, Ritter T, Schreiber S, Woolcott JC, Modesto I, Keating M, Shan K, Wu J, Chiorean MV, Baert F, Dubinsky MC, Goetsch M, Danese S, Feagan BG.   +19 more
europepmc   +1 more source

Janus Kinase Inhibitor Therapy and Risk of Age-Related Macular Degeneration in Autoimmune Disease.

JAMA Ophthalmol
Hallak JA, Abbasi A, Goldberg RA, Modi Y, Zhao C, Jing Y, Chen N, Mercer D, Sahu S, Alobaidi A, López FJ, Luhrs K, Waring JF, den Hollander AI, Smaoui N.   +14 more
europepmc   +1 more source

Corrigendum to: Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials. [PDF]

J Crohns Colitis
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Janus kinase inhibitors: efficacy and safety

Current Opinion in Rheumatology, 2023
Purpose of review Janus kinase inhibitors (JAKi) have been available for the treatment of rheumatoid arthritis (RA) since 2012 and are indicated for patients with active disease despite csDMARD therapy. Efficacy and safety, as demonstrated in the clinical trials, was similar to biologics. A recent post marketing trial suggested
Stanley, Cohen, Virginia, Reddy
openaire   +2 more sources

Janus kinase inhibitors for alopecia areata

Journal of the American Academy of Dermatology, 2023
Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and ...
Brett A, King, Brittany G, Craiglow
openaire   +2 more sources

Investigational Janus kinase inhibitors

Expert Opinion on Investigational Drugs, 2013
Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire   +2 more sources

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

Cochrane Database of Systematic Reviews, 2015
Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non-hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative.
Arturo J, Martí-Carvajal, Vidhu, Anand, Ivan, Solà   +2 more
openaire   +4 more sources

Efficacy of Janus kinase inhibitors in rheumatoid arthritis

Inflammation Research, 2023
Janus kinase inhibitors (JAKis) is a new therapeutic class in autoimmune and inflammatory diseases. Four molecules are approved in rheumatoid arthritis (RA) in Europe. Recently, questions have raised about adverse events. In this context, a synthesis of the efficacy data of JAKis in RA is of use.We performed a literature review based on published ...
Camille, Langbour, Jessica, Rene, Philippe, Goupille, Guillermo, Carvajal Alegria   +3 more
openaire   +2 more sources

Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)

Bioorganic & Medicinal Chemistry Letters, 2009
A series of phenylaminopyrimidines has been identified as inhibitors of Janus kinases (JAKs). Development of this initial series led to the potent JAK2/JAK1 inhibitor CYT387 (N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide). Details of synthesis and SAR studies of these compounds are reported.
Burns, Christopher J., Bourke, David G., Andrau, Laura, Bu, Xianyong, Charman, Susan A., Donohue, Andrew C., Fantino, Emmanuelle, Farrugia, Michelle, Feutrill, John T., Joffe, Max, Kling, Marcel R., Kurek, Margarita, Nero, Tracy L., Nguyen, Thao, Palmer, James T., Phillips, Ian, Shackleford, David M, Sikanyika, Harrison, Styles, Michelle, Su, Stephen, Treutlein, Herbert, Zeng, Jun, Wilks, Andrew F.   +22 more
openaire   +5 more sources